Source:http://linkedlifedata.com/resource/pubmed/id/20636277
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2010-9-27
|
pubmed:abstractText |
Protease inhibitor (PI) resistance-associated mutations (RAMs) are commonly observed in PI-naïve patients who infected with HIV-1 subtype A/E. Few data are available on the genetic mechanisms of PI resistance in non-B HIV-1. This study was aimed to compare PI-RAMs between PI-naïve and -experienced patients and determine PI resistance in each group. Genotypic resistance testing was conducted among a cohort of HIV-1-infected patients who were diagnosed with virologic failure. We studied 137 patients of whom 75 patients were in PI-naïve group and 62 patients in PI-experienced group. Median CD4 cell count and HIV-1 RNA at virologic failure were 169 cells/mm³ and 14,100 copies/mL, respectively. The clinical characteristics between 2 groups were similar (p>0.05) except for the duration of antiretroviral therapy (ART) which was shorter in PI-naïve group (31.5 vs. 46.8 months, p=0.028). Proportion of patients with primary PI-RAMs was 2.7% in PI-naïve and 19% in PI-experienced groups (p=0.002). The most common primary PI-RAMs in the latter group were V82A (10%), I54V (7%) and G48V (4.8%). Proportion of patients with secondary PI-RAMs in the corresponding groups was 99% and 98%, respectively (p=1.000). The most common secondary PI-RAMs in both groups were M36I (91%), H69K (34%) and L89M (30%). In conclusion, primary PI-RAMs are observed exclusively among PI-experienced patients whereas secondary PI-RAMs are equally found in both PI-naïve and PI-experienced patients. Further studies to define virologic response of HIV-1 subtype A/E to various PIs and clinical validation of PI-RAMs in HIV-1 subtype A/E are essentially needed.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1873-4251
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
1
|
pubmed:volume |
8
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
456-60
|
pubmed:meshHeading |
pubmed-meshheading:20636277-Adult,
pubmed-meshheading:20636277-Anti-HIV Agents,
pubmed-meshheading:20636277-Drug Resistance, Viral,
pubmed-meshheading:20636277-Female,
pubmed-meshheading:20636277-Genotype,
pubmed-meshheading:20636277-HIV Infections,
pubmed-meshheading:20636277-HIV Protease,
pubmed-meshheading:20636277-HIV Protease Inhibitors,
pubmed-meshheading:20636277-HIV-1,
pubmed-meshheading:20636277-Humans,
pubmed-meshheading:20636277-Male,
pubmed-meshheading:20636277-Middle Aged,
pubmed-meshheading:20636277-Mutation,
pubmed-meshheading:20636277-Retrospective Studies,
pubmed-meshheading:20636277-Thailand
|
pubmed:year |
2010
|
pubmed:articleTitle |
Comparison of protease inhibitor (PI) resistance-associated mutations between PI-naïve and PI-experienced HIV-1 infected patients in Thailand where subtype A/E is predominant.
|
pubmed:affiliation |
Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|